Dongwoon Anatech is showing strong performance. The news that it confirmed successful results in the second exploratory clinical trial of the world’s first self-developed saliva glucose diagnostic device, ‘D-SaLife,’ appears to be influencing its stock price.
As of 10:13 AM on the 21st, Dongwoon Anatech is trading at 10,860 KRW, up 16.67% compared to the previous day.
According to the International Diabetes Federation (IDF), the number of diabetes patients worldwide last year was 547 million, and including prediabetes and undiagnosed cases, the total reached 1.665 billion. By 2030, these numbers are expected to increase to 642 million and 1.922 billion, respectively. Dongwoon Anatech expects D-SaLife to change the paradigm of the existing blood glucose measurement market, which requires blood sampling, because it allows diabetic patients and the general public who are reluctant to undergo blood sampling to measure glucose without discomfort.
From November last year to April this year, Dongwoon Anatech conducted an exploratory clinical trial of D-SaLife with Professor Seung-Hwan Lee’s research team from the Department of Endocrinology at Catholic University Seoul St. Mary’s Hospital, involving 300 subjects including healthy individuals, hypoglycemic, prediabetic, and hyperglycemic patients.
As the reference standard equipment, the hospital’s certified blood glucose measurement device ‘YSI 2300 STAT PLUS’ was used to verify the correlation and validity with D-SaLife. The comprehensive statistical analysis of the test results was conducted by ‘Medical Excellence,’ a clinical medical professional service company.
The fasting blood glucose values measured by D-SaLife for 300 subjects showed a Pearson Correlation Coefficient of 92.5% compared to the YSI 2300 standard device measurements, demonstrating high correlation and accuracy.
CEO Dongchul Kim stated, "We have sufficiently secured data at the level required by global companies," and added, "We plan to start full-scale overseas license negotiations from the end of this month, aiming to become the world’s first saliva glucose diagnostic device."
Professor Seung-Hwan Lee of Seoul St. Mary’s Hospital, who led the exploratory clinical trial, said, "The accuracy of D-SaLife was higher than initially expected," and added, "Once approved by the Ministry of Food and Drug Safety, it will be a useful device not only for diabetic patients but also for blood glucose management and screening of people in the early stages of diabetes or those with a family history of diabetes."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
